Won Ki Kang

25.4k total citations · 6 hit papers
350 papers, 12.1k citations indexed

About

Won Ki Kang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Won Ki Kang has authored 350 papers receiving a total of 12.1k indexed citations (citations by other indexed papers that have themselves been cited), including 213 papers in Oncology, 194 papers in Pulmonary and Respiratory Medicine and 95 papers in Surgery. Recurrent topics in Won Ki Kang's work include Gastric Cancer Management and Outcomes (146 papers), Colorectal Cancer Treatments and Studies (98 papers) and Gastrointestinal Tumor Research and Treatment (51 papers). Won Ki Kang is often cited by papers focused on Gastric Cancer Management and Outcomes (146 papers), Colorectal Cancer Treatments and Studies (98 papers) and Gastrointestinal Tumor Research and Treatment (51 papers). Won Ki Kang collaborates with scholars based in South Korea, United States and Japan. Won Ki Kang's co-authors include Jeeyun Lee, Joon Oh Park, Se Hoon Park, Ho Yeong Lim, Young Suk Park, Kyoung‐Mee Kim, Seung Tae Kim, Keunchil Park, Tae Sung Sohn and Young Suk Park and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Won Ki Kang

340 papers receiving 11.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial

2009 582 citations Won Ki Kang et al. profile →
Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial

2011 560 citations Jeeyun Lee, Do Hoon Lim et al. Journal of Clinical Oncology profile →
Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone

2012 474 citations Jung Hun Kang, Sung Yong Oh et al. Journal of Clinical Oncology profile →
Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia

2013 366 citations Ho Yeong Lim, Won Ki Kang et al. Journal of Clinical Oncology profile →
Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses

2015 297 citations Se Hoon Park, Tae Sung Sohn et al. Journal of Clinical Oncology profile →
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)

2018 228 citations Won Ki Kang et al. profile →

Peers

Countries citing papers authored by Won Ki Kang

Since Specialization

Citations

This map shows the geographic impact of Won Ki Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Won Ki Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Won Ki Kang more than expected).

Fields of papers citing papers by Won Ki Kang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Won Ki Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Won Ki Kang. The network helps show where Won Ki Kang may publish in the future.

Co-authorship network of co-authors of Won Ki Kang

This figure shows the co-authorship network connecting the top 25 collaborators of Won Ki Kang. A scholar is included among the top collaborators of Won Ki Kang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Won Ki Kang. Won Ki Kang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer 2024 ·Cancer Discovery ·Minae An, Arnav Mehta, Byung‐Hoon Min, You Jeong Heo, Samuel J. Wright, (unknown), Lynn Bi, Hyuk Lee, Tae Jun Kim, (unknown), Jeonghyeon Moon, Ryan J. Park, Matthew R. Strickland, Woong‐Yang Park, Won Ki Kang, Kyoung‐Mee Kim, Seung Tae Kim, Samuel J. Klempner, Jeeyun Lee	26
2	The Optimal Tumor Mutational Burden Cutoff Value as a Novel Marker for Predicting the Efficacy of Programmed Cell Death-1 Checkpoint Inhibitors in Advanced Gastric Cancer 2023 ·Journal of the Korean Gastric Cancer Association ·(unknown), (unknown), (unknown), Sung Hee Lim, Won Ki Kang, Jeeyun Lee, Seung Tae Kim	1
3	Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer 2023 ·Science Advances ·Sujin Hyung, Jihoon Ko, You Jeong Heo, Steven M. Blum, Seung Tae Kim, Se Hoon Park, Joon Oh Park, Won Ki Kang, Ho Yeong Lim, Samuel J. Klempner, Jeeyun Lee	36
4	Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer 2021 ·Clinical Cancer Research ·Seung Tae Kim, Simon A. Smith, Peter G. Mortimer, Arsène‐Bienvenu Loembé, (unknown), Kyoung‐Mee Kim, Claire Smith, Sophie E. Willis, Itziar Irurzun‐Arana, Aliénor Berges, Jung Yong Hong, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Iwanka Kozarewa, Andrew J. Pierce, Emma Dean, Jeeyun Lee	61
5	Analysis of intrapatient heterogeneity of circulating tumor cells at the single-cell level in the cerebrospinal fluid of a patient with metastatic gastric cancer 2020 ·Journal of Cancer Research and Therapeutics ·Jang Ho Cho, (unknown), Sun Young Kim, (unknown), Yong‐Seok Jee, Won Ki Kang, Seung Tae Kim	5
6	MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis 2018 ·Molecular Cancer Therapeutics ·Hee Kyung Kim, (unknown), Heejin Bang, Hee Cheol Kim, Woo Yong Lee, Seong Hyeon Yun, Jeeyun Lee, Su Jin Lee, Young Suk Park, Kyoung‐Mee Kim, Won Ki Kang	40
7	Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer 2018 ·Cancer Chemotherapy and Pharmacology ·Sung Yong Oh, Suee Lee, (unknown), Jeeyun Lee, Seung Tae Kim, Se Hoon Park, Ho Yeong Lim, Won Ki Kang, Byung Woog Kang, Jong Gwang Kim, Hyo Jin Lee, Jung Hoon Kim, Jung Hun Kang, HoUng Kim	7
8	Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial 2018 ·Journal of the Korean Gastric Cancer Association ·(unknown), Kyoung‐Mee Kim, Min Gew Choi, Jun Ho Lee, Tae Sung Sohn, Jae-Moon Bae, (unknown), Su Jin Lee, Seung Tae Kim, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Se Hoon Park	9
9	Phase II trial of dacomitinib in patients with HER2-positive gastric cancer 2015 ·Gastric Cancer ·Do‐Youn Oh, (unknown), Y. Choi, Won Ki Kang, Seock‐Ah Im, Jin Won Kim, Yung‐Jue Bang	35
10	Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients 2015 ·Oncotarget ·Seung Tae Kim, Won‐Suk Lee, Richard B. Lanman, Stefanie Mortimer, Oliver A. Zill, Kyoung-Mee Kim, Kee Taek Jang, Seok Hyung Kim, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Helmy Eltoukhy, Won Ki Kang, Woo Yong Lee, Hee‐Cheol Kim, Keunchil Park, Jeeyun Lee, AmirAli Talasaz	63
11	Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification 2014 ·Molecular Cancer Therapeutics ·Seung Tae Kim, (unknown), Su Jin Lee, Jeeyun Lee, Yoon‐La Choi, Kyoung‐Mee Kim, Jeonghee Cho, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Masakazu Yashiro, Won Ki Kang, Joon Oh Park	35
12	CD151 Overexpression is Associated with Poor Prognosis in Patients with pT3 Gastric Cancer 2013 ·Annals of Surgical Oncology ·Sang Yun Ha, In‐Gu Do, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Won Ki Kang, Min Gew Choi, Jun Ho Lee, Jae Moon Bae, Sung Hoon Kim, Kyoung‐Mee Kim, Tae Sung Sohn	12
13	Inhibition of Monocarboxylate Transporter 2 Induces Senescence-Associated Mitochondrial Dysfunction and Suppresses Progression of Colorectal Malignancies In Vivo 2012 ·Molecular Cancer Therapeutics ·In‐Kyoung Lee, (unknown), Won Ki Kang, Chaehwa Park	20
14	Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial breakdown → 2011 ·Journal of Clinical Oncology ·Jeeyun Lee, Do Hoon Lim, Sung Kim, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Min Gew Choi, Tae Sung Sohn, Jae Hyung Noh, Jae Moon Bae, Yong Chan Ahn, Insuk Sohn, Sin Ho Jung, Cheol Keun Park, Kyoung‐Mee Kim, Won Ki Kang	560
15	Polymorphic markers associated with severe oxaliplatin‐induced, chronic peripheral neuropathy in colon cancer patients 2011 ·Cancer ·Hong‐Hee Won, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Jong‐Won Kim, Soo‐Youn Lee, Se Hoon Park	73
16	Knockdown of Inwardly Rectifying Potassium Channel Kir2.2 Suppresses Tumorigenesis by Inducing Reactive Oxygen Species–Mediated Cellular Senescence 2010 ·Molecular Cancer Therapeutics ·In‐Kyoung Lee, Chaehwa Park, Won Ki Kang	29
17	A Novel Senescence-Evasion Mechanism Involving Grap2 and Cyclin D Interacting Protein Inactivation by Ras Associated with Diabetes in Cancer Cells under Doxorubicin Treatment 2010 ·Cancer Research ·In‐Kyoung Lee, (unknown), (unknown), Won Ki Kang, Chaehwa Park	26
18	The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma 2007 ·Blood ·Sarah Park, Jeeyun Lee, Young Hyeh Ko, Arum Han, Hyun Jung Jun, Sang Chul Lee, In Gyu Hwang, Winnie Yeo, Jin Seok Ahn, Chul Won Jung, Kihyun Kım, Yong Chan Ahn, Won Ki Kang, Keunchil Park, Won Seog Kim	242
19	Influence of small interfering RNA corresponding to ets homologous factor on senescence-associated modulation of prostate carcinogenesis 2006 ·Molecular Cancer Therapeutics ·Chaehwa Park, In‐Kyoung Lee, Won Ki Kang	18
20	Interferon-α resistance can be reversed by inhibition of IFN-α-induced COX-2 expression potentially via STAT1 activation in A549 cells 2006 ·Oncology Reports ·Jeeyun Lee, (unknown), Young‐Hyuck Im, (unknown), Joon Park, Kihyun Kım, Won Il Kim, Jin Seok Ahn, (unknown), Young Min Park, Won Ki Kang, Keunchil Park	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact